TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37041522

Group type: EXPERIMENTAL
Intervention: Curative intent surgery (surgery with curative intent)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Palliative chemotherapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) assessment (EORTC-QLQ-C30)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Performance status association with HRQoL
Number of subjects: 100
Study: 37041539

Group type: EXPERIMENTAL
Intervention: Filapixant 80 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Filapixant 250 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 37041561

Group type: EXPERIMENTAL
Intervention: EIT-guided PEEP titration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low fraction of inspired oxygen (FiO2)
Number of subjects: 0
Study: 37041600

Group type: EXPERIMENTAL
Intervention: Nurse-to-family telehealth
Number of subjects: 6

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6
Study: 37041669

Group type: EXPERIMENTAL
Intervention: BI + peer
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: BI + web
Number of subjects: 739

Group type: COMPARATOR
Intervention: EUC
Number of subjects: 739
Study: 37041704

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 97
Study: 37041967

Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ritonavir
Number of subjects: 1859

Group type: COMPARATOR
Intervention: Other SARS-CoV-2 directed treatment
Number of subjects: 1859
Study: 37042037

Group type: EXPERIMENTAL
Intervention: Combination of dabrafenib (150 mg twice daily), trametinib (2 mg once daily), and AT13387 (260 mg/m)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combination of dabrafenib, trametinib, and AT13387
Number of subjects: 22
Study: 37042110

Group type: EXPERIMENTAL
Intervention: Layperson-delivered telephone program focusing on empathy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 58
Study: 37042129

Group type: EXPERIMENTAL
Intervention: FGFR inhibitors (Infigratinib, futibatinib, pemigatinib)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FGFR inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: gemcitabine/cisplatin
Number of subjects: 0
Study: 37042205

Group type: EXPERIMENTAL
Intervention: BYON3521
Number of subjects: 0
Study: 37042284

Group type: EXPERIMENTAL
Intervention: Clopidogrel monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite of all-cause mortality, nonfatal myocardial infarction, stroke, acute coronary syndrome, or BARC bleeding type ≥3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BARC bleeding types 2 to 5
Number of subjects: 0
Study: 37042306

Group type: EXPERIMENTAL
Intervention: Digital self-control intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 0
Study: 37042316

Group type: EXPERIMENTAL
Intervention: Vacuum-assisted biopsy (VAB)
Number of subjects: 1470

Group type: COMPARATOR
Intervention: Core needle biopsy (CNB)
Number of subjects: 1470
Study: 37042345

Group type: EXPERIMENTAL
Intervention: E-cigarette
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Heated Tobacco Product (HTP)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Usual Brand Combustible Cigarette (UBC)
Number of subjects: 22

Group type: COMPARATOR
Intervention: E-cigarette and HTP vs UBC
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: E-cigarette vs HTP
Number of subjects: 22
Study: 37042545

Group type: COMPARATOR
Intervention: 10 mg rizatriptan
Number of subjects: 133

Group type: COMPARATOR
Intervention: 2.5 mg zolmitriptan
Number of subjects: 133

Group type: COMPARATOR
Intervention: Triptans (combined data from both studies)
Number of subjects: 133
Study: 37042653

Group type: EXPERIMENTAL
Intervention: Morning Serum Cortisol
Number of subjects: 0
Study: 37042724

Group type: EXPERIMENTAL
Intervention: Chemotherapy (ADjuVANt Chemotherapy in the Elderly trial)
Number of subjects: 40
Study: 37042865

Group type: EXPERIMENTAL
Intervention: Momelotinib
Number of subjects: 725
Study: 37042921

Group type: EXPERIMENTAL
Intervention: Alemtuzumab levels ≤0.32 μg/mL
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Alemtuzumab levels >0.32 μg/mL
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Day 0 alemtuzumab levels >0.32 μg/mL
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CXCL9 levels ≤2394 pg/mL (day 14+ median)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CXCL9 levels >2394 pg/mL (day 14+)
Number of subjects: 33
Study: 37043021

Group type: EXPERIMENTAL
Intervention: Robot-assisted cochlear implant surgery (RACIS)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional cochlear implantation
Number of subjects: 23
Study: 37043192

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 5438

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 5438
Study: 37043197

Group type: EXPERIMENTAL
Intervention: Aerosol box (SplashGuard CG)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control (no aerosol box)
Number of subjects: 122
Study: 37043201

Group type: EXPERIMENTAL
Intervention: Intrapleural tissue plasminogen activator plus deoxyribonuclease therapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Surgical decortication
Number of subjects: 26
Study: 37043203

Group type: EXPERIMENTAL
Intervention: Conditioned Open-label Placebo (C-OLP) with methadone
Number of subjects: 131

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) with methadone
Number of subjects: 131
Study: 37043210

Group type: EXPERIMENTAL
Intervention: Endocrine therapy alone (recurrence score <11)
Number of subjects: 9369

Group type: EXPERIMENTAL
Intervention: Endocrine therapy alone vs chemotherapy followed by endocrine therapy (recurrence score 11-25)
Number of subjects: 9369

Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by endocrine therapy (recurrence score >25)
Number of subjects: 9369

Group type: EXPERIMENTAL
Intervention: Asian race
Number of subjects: 9369

Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 9369

Group type: EXPERIMENTAL
Intervention: Locoregional recurrence (LRR)
Number of subjects: 9369
Study: 37043216

Group type: EXPERIMENTAL
Intervention: Smartphone app-assisted follow-up
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional in-person follow-up
Number of subjects: 72
Study: 37043227

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 552

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Upadacitinib
Number of subjects: 552
Study: 37043263

Group type: EXPERIMENTAL
Intervention: My Mobile Wallet intervention (real-time adherence monitors, SMS reminders, and mobile money incentives)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: My Mobile Wallet intervention
Number of subjects: 30
Study: 37043271

Group type: EXPERIMENTAL
Intervention: Web-based tailored intervention (parent-targeted, focused on 6 weight-related behaviors)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Web-based tailored intervention (log-in duration for PA session)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Web-based tailored intervention (log-in duration for sedentary behavior session)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Web-based health education comparison program
Number of subjects: 119
Study: 37043339

Group type: EXPERIMENTAL
Intervention: 1% atropine weekly for 6 months
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: 0.01% atropine daily for 6 months (phase 2)
Number of subjects: 207

Group type: COMPARATOR
Intervention: 0.01% atropine daily for 1 year (group B)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: 1% atropine
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: 1% atropine (phase 1)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: 0.01% atropine (phase 2)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: 0.01% atropine
Number of subjects: 207
Study: 37043386

Group type: EXPERIMENTAL
Intervention: Baseline high-sensitivity troponin T (hsTnT) ≥14 ng/L
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: 6-predictor model including age, sex, eGFR <45 mL·min -1 ·1.73 m -2, functional capacity <4 METs or unknown, NT-proBNP ≥300 pg/mL, and estimated intraoperative blood loss
Number of subjects: 732
Study: 37043404

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 37043520

Group type: EXPERIMENTAL
Intervention: 20 mmol KCl intravenous injection
Number of subjects: 81
Study: 37043518

Group type: EXPERIMENTAL
Intervention: Congenital combined pituitary hormone deficiency (cCPHD) diagnosed before age 18 years
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Congenital combined pituitary hormone deficiency (cCPHD) diagnosed <1 year
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Congenital combined pituitary hormone deficiency (cCPHD) diagnosed 1-17 years
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Congenital combined pituitary hormone deficiency (cCPHD)
Number of subjects: 128
Study: 37043555

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37043653

Group type: EXPERIMENTAL
Intervention: Dersimelagon 100 mg once daily for 16 weeks
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Dersimelagon 300 mg once daily for 16 weeks
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 37043652

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 11000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11000
Study: 37043654

Group type: COMPARATOR
Intervention: Male donor group
Number of subjects: 8719

Group type: EXPERIMENTAL
Intervention: Female donor group
Number of subjects: 8719
Study: 37043729

Group type: EXPERIMENTAL
Intervention: Modified Pap test
Number of subjects: 266

Group type: COMPARATOR
Intervention: Traditional Pap test
Number of subjects: 266
Study: 37044158

Group type: EXPERIMENTAL
Intervention: ENDS users
Number of subjects: 395

Group type: COMPARATOR
Intervention: Cigarette users
Number of subjects: 395
Study: 37044281

Group type: EXPERIMENTAL
Intervention: Oral NaCl (2 grams 3 times a day)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Oral NaCl
Number of subjects: 65
Study: 37044318

Group type: EXPERIMENTAL
Intervention: t-Branch graft
Number of subjects: 80
Study: 37044364

Group type: EXPERIMENTAL
Intervention: Multifaceted strategy with a multidisciplinary approach including telehealth tools, continued education, pharmacological and non-pharmacological treatment, and behavioral change.
Number of subjects: 35

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 35
Study: 37045473

Group type: EXPERIMENTAL
Intervention: Adoptive transfer of autologous tumor infiltrating lymphocytes (TILs) that recognize tumor-specific point mutations.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TILs targeting cancer-specific mutations and other genetic aberrations such as gene fusions.
Number of subjects: 0
Study: 37045498

Group type: EXPERIMENTAL
Intervention: DCB-only angioplasty
Number of subjects: 1139

Group type: COMPARATOR
Intervention: DES
Number of subjects: 1139
Study: 37045500

Group type: EXPERIMENTAL
Intervention: Abbreviated antiplatelet therapy (APT)
Number of subjects: 4579

Group type: COMPARATOR
Intervention: Standard antiplatelet therapy (APT)
Number of subjects: 4579

Group type: EXPERIMENTAL
Intervention: Routine care period
Number of subjects: 4579
Study: 37045504

Group type: EXPERIMENTAL
Intervention: CYP2C19 genotyping with clopidogrel-based therapy (RMs or NMs)
Number of subjects: 8163

Group type: COMPARATOR
Intervention: CYP2C19 genotyping with clopidogrel-based therapy (IMs or PMs)
Number of subjects: 8163
Study: 37045543

Group type: EXPERIMENTAL
Intervention: DTI-ALPS index (first quartile)
Number of subjects: 2219
Study: 37045544

Group type: EXPERIMENTAL
Intervention: Catfish stent retriever
Number of subjects: 238
Study: 37045546

Group type: EXPERIMENTAL
Intervention: Salpingectomy with delayed oophorectomy
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Salpingo-oophorectomy
Number of subjects: 1500
Study: 37045565

Group type: EXPERIMENTAL
Intervention: Dopamine or Epinephrine administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blood transfusion
Number of subjects: 0
Study: 37045569

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (1.6%) + chondroitin sulfate (2%) therapy (Ialuril)
Number of subjects: 80
Study: 37045570

Group type: EXPERIMENTAL
Intervention: Hidden pain conditioning with positive induced expectations (G1)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Positive expectations (G2)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Neutral expectations (G3)
Number of subjects: 264
Study: 37045574

Group type: EXPERIMENTAL
Intervention: COVID Psychosocial Impacts Scale (CPIS)
Number of subjects: 3500

Group type: EXPERIMENTAL
Intervention: Established measures of psychological distress, post-traumatic stress, well-being, and post-traumatic growth
Number of subjects: 3500
Study: 37045708

Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone (LDN) 4.5 mg for 8 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 23
Study: 37045845

Group type: EXPERIMENTAL
Intervention: Percutaneous spinal cord epidural stimulation (SCES)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Temporary SCES implantation
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Permanent SCES implantation
Number of subjects: 2
Study: 37046093

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37046095

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37046094

Group type: EXPERIMENTAL
Intervention: Antibodies against endogenous retroviruses
Number of subjects: 0
Study: 37046096

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37046122

Group type: EXPERIMENTAL
Intervention: 8 g per day I + AX for 21 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Weight-matched maltodextrin control
Number of subjects: 20
Study: 37046178

Group type: EXPERIMENTAL
Intervention: PrEP users
Number of subjects: 2567

Group type: EXPERIMENTAL
Intervention: Younger participants
Number of subjects: 2567

Group type: EXPERIMENTAL
Intervention: Participants with lower self-esteem
Number of subjects: 2567

Group type: EXPERIMENTAL
Intervention: Participants with higher depression scores
Number of subjects: 2567

Group type: EXPERIMENTAL
Intervention: Participants encouraged by their main partner
Number of subjects: 2567

Group type: EXPERIMENTAL
Intervention: Participants encouraged by friends
Number of subjects: 2567

Group type: EXPERIMENTAL
Intervention: Participants with knowledge of their partner's HIV status
Number of subjects: 2567

Group type: EXPERIMENTAL
Intervention: Participants using PrEP and/or condoms
Number of subjects: 2567
Study: 37046213

Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation (PCV)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Pressure support ventilation (PSV)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Spontaneous breathing (SB) after extubation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Controlled ventilation
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Restart of spontaneous breathing
Number of subjects: 23
Study: 37046259

Group type: EXPERIMENTAL
Intervention: XGBoost pre-pandemic model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deep Learning pre-pandemic model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: XGBoost during first pandemic wave
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deep Learning during first pandemic wave
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: XGBoost augmented with first wave data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deep Learning augmented with first wave data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: XGBoost first phase after re-training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deep Learning first phase after re-training
Number of subjects: 0
Study: 37046290

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy (CBT) for tinnitus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Internet-delivered mindfulness-based tinnitus stress reduction intervention (MBTSR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 0
Study: 37046343

Group type: EXPERIMENTAL
Intervention: LACI (left atrioventricular coupling index) assessment
Number of subjects: 1046

Group type: EXPERIMENTAL
Intervention: LACI cut-off at 34.7%
Number of subjects: 1046

Group type: EXPERIMENTAL
Intervention: LACI
Number of subjects: 1046

Group type: EXPERIMENTAL
Intervention: LACI assessment in high-risk patients with impaired LV systolic function (LVEF ≤ 35%)
Number of subjects: 1046
Study: 37046380

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (CTR)
Number of subjects: 72
Study: 37046452

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Gemifloxacin
Number of subjects: 60
Study: 37046466

Group type: EXPERIMENTAL
Intervention: Surgeon-performed POCUS
Number of subjects: 100
Study: 37046681

Group type: EXPERIMENTAL
Intervention: Fluvastatin (6 mg/kg/day) with Celecoxib (fixed daily dose)
Number of subjects: 20
Study: 37046849

Group type: EXPERIMENTAL
Intervention: Cetuximab combined with 5-fluorouracil and cisplatin (6 cycles)
Number of subjects: 65
Study: 37047973

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37048055

Group type: EXPERIMENTAL
Intervention: Women with PCOS
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: miR-28-3p, miR-139-5p, miR-376a-3p (after follow-up)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: miR-139-5p
Number of subjects: 46
Study: 37048135

Group type: EXPERIMENTAL
Intervention: Copeptin
Number of subjects: 219

Group type: COMPARATOR
Intervention: hs-cTnT
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Combination of copeptin and hs-cTnT
Number of subjects: 219

Group type: COMPARATOR
Intervention: Acute HF
Number of subjects: 219

Group type: COMPARATOR
Intervention: NSTE-ACS
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: All-cause mortality
Number of subjects: 219
Study: 37048598

Group type: EXPERIMENTAL
Intervention: Rhythmic median nerve stimulation (MNS) at 10 Hz
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Rhythmic median nerve stimulation (MNS) at 12 Hz
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Arrhythmic median nerve stimulation (MNS) at 12 Hz
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no stimulation)
Number of subjects: 32
Study: 37048629

Group type: EXPERIMENTAL
Intervention: Median Nerve Stimulation (MNS) at 12 Hz for 4 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS) unit for MNS
Number of subjects: 31
Study: 37049546

Group type: EXPERIMENTAL
Intervention: Psychobiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37049576

Group type: EXPERIMENTAL
Intervention: Food supplement (probiotics, prebiotics, vitamin D, zinc, and selenium)
Number of subjects: 162
Study: 37050861

Group type: EXPERIMENTAL
Intervention: Venglustat administered as food admixture
Number of subjects: 0
Study: 37050937

Group type: EXPERIMENTAL
Intervention: Plasma ceramide levels (C16:0, C18:0, C20:0, C24:1, C24:2) measured at admission
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Combination of Global Registry of Acute Coronary Events (GRACE) score with ceramides
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Long-chain ceramides and very-long-chain ceramides measurements
Number of subjects: 826
Study: 37051014

Group type: EXPERIMENTAL
Intervention: Participants' estimates of others' cannabis use (weekly or more often)
Number of subjects: 744

Group type: COMPARATOR
Intervention: General population survey reports of cannabis use
Number of subjects: 744
Study: 37051129

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (PN) from postoperative day 1 to day 5 plus oral food 'at will' (treatment arm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral food 'at will' alone (control arm)
Number of subjects: 0
Study: 37051203

Group type: EXPERIMENTAL
Intervention: Skeletal group (n=300)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Muscular/pain group (n=73)
Number of subjects: 468
Study: 37051564

Group type: EXPERIMENTAL
Intervention: Telerehabilitation programme combined with continuous positive airway pressure
Number of subjects: 180

Group type: COMPARATOR
Intervention: Continuous positive airway pressure alone
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 180
Study: 37051646

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus ovarian function suppression (T+OFS group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Tamoxifen (T group)
Number of subjects: 39
Study: 37051752

Group type: EXPERIMENTAL
Intervention: CKD-EPI creatinine-cystatin equation
Number of subjects: 1966

Group type: COMPARATOR
Intervention: Creatinine-only equation
Number of subjects: 1966

Group type: EXPERIMENTAL
Intervention: Group 1 (lower eGFR with creatinine-cystatin)
Number of subjects: 1966

Group type: EXPERIMENTAL
Intervention: Group 3 (higher eGFR with creatinine-cystatin)
Number of subjects: 1966

Group type: EXPERIMENTAL
Intervention: Increasing difference in eGFR (due to lower eGFR with creatinine-cystatin)
Number of subjects: 1966
Study: 37051756

Group type: EXPERIMENTAL
Intervention: Venetoclax 600 mg daily with azacitidine during induction cycles; maintenance arms included azacitidine with 400 mg venetoclax or 400 mg venetoclax alone.
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: MRD-negative patients by flow cytometry
Number of subjects: 42

Group type: COMPARATOR
Intervention: MRD guidance for azacitidine discontinuation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Venetoclax doses >400 mg with azacitidine
Number of subjects: 42
Study: 37051799

Group type: EXPERIMENTAL
Intervention: Weight-based non-ICU HFNC protocols
Number of subjects: 36

Group type: COMPARATOR
Intervention: Age-based non-ICU HFNC protocols
Number of subjects: 36

Group type: COMPARATOR
Intervention: ICU-only HFNC protocols
Number of subjects: 36
Study: 37051821

Group type: EXPERIMENTAL
Intervention: Glenohumeral joint corticosteroid injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Suprascapular nerve block
Number of subjects: 40